Pancreatic Bud Cell Differentiation via KGF EGF BMP Inhibitor Culture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating insulin-producing cells from pluripotent stem cells fail to achieve glucose responsiveness in vivo, limiting their effectiveness for treating pancreatic diseases like diabetes.
Innovation Solution
The method involves inducing differentiation of PDX1 +/NKX6.1 - cells into pancreatic bud cells by culturing them in a medium containing KGF, EGF, and a BMP inhibitor, which forms cellular aggregates, allowing for the production of insulin-producing cells that respond to glucose levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If insulin-producing cells are generated from pluripotent stem cells using conventional differentiation methods, then insulin production capability is achieved, but glucose responsiveness in vivo is not attained
Solution Approach 1:
The differentiation process is divided into distinct stages: first generating pancreatic bud cells with specific markers (PDX1+, NKX6.1+, SOX9+), then allowing in vivo maturation into glucose-responsive insulin-producing cells. This segmentation enables control over intermediate cell states that lead to functional maturity in the living body.
Solution Approach 2:
Pancreatic bud cells are prepared in advance with specific molecular markers and differentiation characteristics before transplantation. The cells are pre-differentiated to a stage where they can complete their maturation and acquire glucose responsiveness in vivo, rather than attempting to achieve full functionality entirely in vitro.
2Reliability
If pancreas or pancreatic islet transplantation is performed, then blood glucose control is improved, but immunosuppression and organ availability become problematic
Solution Approach 1:
Instead of transplanting whole pancreas or islet organs, the invention creates cell aggregates that copy the essential functional units (pancreatic bud cells) which can then mature into insulin-producing cells in vivo. This cellular-level copying reduces immunogenicity compared to whole organ transplantation.
Solution Approach 2:
The invention changes the scale of transplantation from whole organs or islets to smaller cell aggregates, and changes the differentiation state from mature insulin-producing cells to precursor pancreatic bud cells that complete maturation in vivo. These parameter changes reduce immune recognition and improve compatibility.
3Manufacturing precision
If pancreatic bud cells are cultured to induce differentiation, then cellular aggregation occurs, but control over differentiation timing and completeness becomes challenging
Solution Approach 1:
The culture system allows pancreatic progenitor cells to self-organize into aggregates and self-differentiate into pancreatic bud cells through their intrinsic biological programs. The culture conditions provide necessary growth factors (KGF, EGF, BMP inhibitors) but the cells themselves drive the aggregation and differentiation process, reducing the need for complex external control mechanisms.
Data Source
Figure 1
Figure 2~3
Figure 4A~4B
AI summary
Provided is a method for generating pancreatic bud cells, having the step of culturing PDX1+/NKX6.1- cells in a medium containing KGF, EGF and a BMP inhibitor. The culturing step may be performed in suspension cultures or in adherent cultures. When the cells are cultured in adherent cultures, the cells may be cultured in a medium further containing a ROCK inhibitor or a nonmuscle myosin II inhibitor.